Patents Examined by Changhwa J. Cheu
-
Patent number: 11977083Abstract: Compositions and methods are provided for diagnosis and/or prognosis of cardiovascular diseases or events in a subject. In some embodiments, the method includes measuring and comparing the level of particular proteins to other proteins. In other embodiments, the method includes comparison with clinical variable information.Type: GrantFiled: October 27, 2020Date of Patent: May 7, 2024Assignee: PREVENCIO, INC.Inventors: Rhonda Fay Rhyne, Craig Agamemnon Magaret, John Edward Strobeck, James Louis Januzzi, Jr.
-
Patent number: 11977080Abstract: Disclosed is a method for acquiring information of a target polypeptide, comprising: acquiring a diffusion time of a fluorescently labeled target polypeptide and a diffusion time of each of a plurality of fluorescently labeled reference polypeptides by fluorescence correlation spectroscopy or fluorescence cross-correlation spectroscopy, and acquiring information on size of the fluorescently labeled target polypeptide from the diffusion time of the fluorescently labeled target polypeptide with reference to the diffusion times of the plurality of fluorescently labeled reference polypeptides, wherein information on size of each of the plurality of fluorescently labeled reference polypeptides is known, and the sizes of the plurality of reference polypeptides are different from each other.Type: GrantFiled: April 27, 2021Date of Patent: May 7, 2024Assignees: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, SYSMEX CORPORATIONInventors: Masataka Kinjo, Akshay Ganguly, Lausonia Ramaswamy
-
Patent number: 11971408Abstract: The present invention, in some embodiments thereof, generally relates to methods and devices for determining the health status of a subject, e.g., whether the subject has a disease or other condition. In some embodiments, a plurality or mixture of species may be differentially solubilized in a single two-phase aqueous system, or other multi-phase aqueous system. The nature or degree of the solubilization of the species may be used to determine the health status of a subject. For example, some embodiments are directed to devices and methods for determining a disease or other condition as a function of the changes to the structure of two or more species. The species may be selected based on their differential solubility behavior in a two-phase or other multi-phase aqueous system.Type: GrantFiled: February 28, 2020Date of Patent: April 30, 2024Assignee: Cleveland Diagnostics, Inc.Inventors: Arnon Chait, Boris Y. Zaslavsky
-
Patent number: 11965893Abstract: This invention relates to the use of biomarker LRG1 as a biomarker for preeclampsia for use from the first trimester. Elevated levels of leucine-rich alpha 2 glycoprotein 1 (LRG1) can predict risk for the future development of preeclampsia or other hypertensive disorders of pregnancy. The predictive test will comprise the measurement of LRG1 protein, peptide fragment, DNA or RNA, from either blood, plasma, serum, urine, saliva or amniotic fluid. The invention provides a method and a test kit to assess the risk of pre-eclampsia in pregnant woman. The method or test can utilise antibodies to measure levels of LGR1 in a sample.Type: GrantFiled: July 7, 2022Date of Patent: April 23, 2024Assignee: The Queen's University of BelfastInventors: Chris Watson, Timothy Lyons, Alice Cheung, Clare Kelly
-
Patent number: 11951483Abstract: The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.Type: GrantFiled: March 29, 2021Date of Patent: April 9, 2024Assignee: MESO SCALE TECHNOLOGIES, LLC.Inventors: Eli N. Glezer, Sudeep Kumar, Pankaj Oberoi, George Sigal, Michael Tsionsky
-
Patent number: 11953506Abstract: Methods for monitoring inflammation status of a subject comprise determining levels of at least one neutrophil activation marker, or at least three markers, in urine samples taken from the subject at multiple time points, wherein increased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample are indicative of or predictive of an exacerbation of inflammation and/or wherein decreased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample following an increase are indicative or predictive of recovery from, or successful treatment of, an exacerbation of inflammation. Corresponding systems, test kits and computer programs are provided.Type: GrantFiled: February 6, 2020Date of Patent: April 9, 2024Assignee: MOLOGIC LIMITEDInventors: Gita Parekh, Paul Davis
-
Patent number: 11946939Abstract: Provided herein are methods for assessing risk of infection or cardiovascular disease (CVD) in a subject with an inflammatory disease, e.g., rheumatoid arthritis. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers with or without additional clinical variables to assess infection and CVD risk. Also provided are uses of inflammatory biomarkers for guiding treatment decisions.Type: GrantFiled: March 15, 2021Date of Patent: April 2, 2024Assignee: Laboratory Corporation of America HoldingsInventors: Kerri Ford, Jeffrey R. Curtis
-
Patent number: 11946935Abstract: Methods and diagnostic compositions for detecting and monitoring meningiomas.Type: GrantFiled: August 25, 2021Date of Patent: April 2, 2024Assignee: Regents of the University of MinnesotaInventors: Nurten Saydam, Okay Saydam
-
Patent number: 11933792Abstract: This invention provides reagents and methods for diagnosing renal disease. Differential levels of inosine metabolite, and proteins: apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, or fibrinogen A-alpha chain, kininogen, Inter-Alpha Inhibitor H4 (ITIH4), keratin Type I cytoskeletol 10 cystatin A, cystatin B and other polypeptides and fragments thereof provide biomarkers of renal disease and are described herein.Type: GrantFiled: July 28, 2022Date of Patent: March 19, 2024Assignee: IDEXX Laboratories, Inc.Inventors: Mahalakshimi Yerramilli, Michael Randolph Atkinson, Murthy V. S. N. Yerramilli
-
Patent number: 11927594Abstract: The present disclosure describes a method of quantifying amounts of phosphopeptides using isotopically-enriched peptides as internal standards. A kit comprising at least one isotopically-enriched phosphorylated peptide can be used to quantify changes in amounts of phosphopeptides using parallel reaction monitoring mass spectrometry techniques. The invention can be used to indicate the pathologic mechanism, severity of the disease, and treatment response of a subject. The invention can also be used to identify subjects who require more aggressive therapeutic interventions or alternative treatments.Type: GrantFiled: February 7, 2020Date of Patent: March 12, 2024Assignee: RENSSELAER CENTER FOR TRANSLATIONAL RESEARCH, INC.Inventor: Lawrence S. Zisman
-
Patent number: 11921117Abstract: The present specification discloses methods of characterizing a population of particles using a particle analyzer. Particles may be characterized by size, absolute number, whether the particle is non-proteinaceous or proteinaceous, whether a proteinaceous particle has or lacks a certain physical property, or any combination thereof.Type: GrantFiled: March 11, 2019Date of Patent: March 5, 2024Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Mantas Malisauskas, Christian Lubich, Thomas Prenninger, Birgit Reipert
-
Patent number: 11921120Abstract: This invention provides reagents, methods and biochemical markers for identifying and providing therapeutic intervention for individuals with metabolic dysfunction, or individuals at risk for metabolic dysfunction.Type: GrantFiled: March 14, 2021Date of Patent: March 5, 2024Assignee: Duke UniversityInventors: John F. Rawls, James E. N. Minchin
-
Patent number: 11913948Abstract: The present invention relates to a method for improving the detection and diagnosis targeting biomarkers using an aqueous two-phase system (ATPS). In one embodiment, the present invention provides a method for improving a diagnostic procedure involving the detection or quantification of one or more biomarkers in liquid biopsy, the method comprises contacting a porous material embedded with ATPS components with a liquid biopsy containing the biomarkers, purifying and concentrating the target biomarkers, and providing a product comprising the target biomarkers for performing the diagnostic procedure.Type: GrantFiled: May 17, 2022Date of Patent: February 27, 2024Assignee: PHASE SCIENTIFIC INTERNATIONAL, LTD.Inventor: Yin To Chiu
-
Patent number: 11913939Abstract: Methods and systems for performing assays in compartmentalized nano-volumes to screen for functional bispecific or multispecific biologics, including: providing a plurality of at least two distinct types of cells, wherein two or more first-type cells are engineered to express substantially a single genetic-variant per cell for a bispecific or multispecific biologic in a secreted form, wherein two or more second-type cells are selected or engineered to produce a positive reporter molecule signal that is triggered by a functional variant of the said biologic expressed by a first-type cell; providing a plurality of compartmentalized nano-volumes, wherein two or more nano-volumes are each provided with substantially one first-type cell, and one or more second-type cell(s); incubating the said nano-volumes over a period of time to allow the expression and secretion of the said biologics inside the said nano-volumes; collecting data representing the positive reporter molecule signal triggered by secreted biologicsType: GrantFiled: April 2, 2021Date of Patent: February 27, 2024Assignee: Amberstone Biosciences, Inc.Inventors: George Guikai Wu, Yonglei Shang
-
Patent number: 11891443Abstract: The present invention provides an antibody recognizing a v9 fragment of the cell adhesion molecule CADM1.Type: GrantFiled: March 18, 2019Date of Patent: February 6, 2024Assignee: The University of TokyoInventors: Yoshinori Murakami, Takeshi Ito, Takao Hamakubo, Hiroko Iwanari
-
Patent number: 11878065Abstract: The present invention relates to reporter protein fusion antibodies, transgenic animals expressing the same, and methods of using the reporter protein fusion antibodies.Type: GrantFiled: August 8, 2019Date of Patent: January 23, 2024Inventor: Xiaofeng Xia
-
Patent number: 11874281Abstract: Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.Type: GrantFiled: October 14, 2021Date of Patent: January 16, 2024Assignee: Enzo Life Sciences, Inc.Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, Joshua Rabbani, Praveen Pande
-
Patent number: 11860162Abstract: The present invention relates to methods for identifying markers for systemic lupus erythematosus (SLE) and to the markers identified with the aid of this method, which can differentiate between SLE and other autoimmune diseases on the one hand and between different SLE subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in SLE. The invention also relates to methods for screening and validating active substances for application in SLE subgroups.Type: GrantFiled: July 6, 2020Date of Patent: January 2, 2024Assignee: Oncimmune Germany GmbHInventors: Angelika Luking, Peter Schulz-Knappe, Carmen Theek, Petra Budde, Anna Telaar
-
Patent number: 11860166Abstract: Provided are a red fluorescent protein-based biosensor for measuring the activity of dopamine receptor D1, a method of measuring the activity of dopamine receptor D1 using the biosensor, and a method of detecting a ligand binding to dopamine receptor D1.Type: GrantFiled: January 31, 2020Date of Patent: January 2, 2024Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Jihye Seong, Hyun-bin Kim
-
Patent number: 11851487Abstract: Provided herein are conformation-specific antibodies which bind to protein aggregates, such as amyloid fibrils, including aggregates of glucagon and liraglutide. Also provided are methods of using the antibodies to detect protein aggregates in samples, and methods for identifying aggregate-binding antibodies.Type: GrantFiled: August 15, 2019Date of Patent: December 26, 2023Inventor: Peter M. Tessier